• Tonix Pharmaceuticals Holding Corp TNXP.OQ reported a quarterly adjusted loss of $2.84​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-576.00. The mean expectation of two analysts for the quarter was for a loss of $3.23 per share. Wall Street expected results to range from $-3.37 to $-3.09 per share.

• Revenue fell 2.1% to $2.43 million from a year ago; analysts expected $2.55 million.

• Tonix Pharmaceuticals Holding Corp's reported EPS for the quarter was a loss of $2.84​.

• The company reported a quarterly loss of $16.83 million.

• Tonix Pharmaceuticals Holding Corp shares had risen by 5.3% this quarter and lost 42.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 99.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Tonix Pharmaceuticals Holding Corp is $70.00

This summary was machine generated from LSEG data May 12 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)